Nicotinamide riboside did not improve early Parkinson disease
In a 52-week randomised trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.
JAMA
In a randomised, double-blind, placebo-controlled trial across 11 centres in Norway, researchers assigned 410 patients with early Parkinson disease to receive oral nicotinamide riboside, 500 mg twice daily, or a placebo for 52 weeks. The primary analysis included 393 participants, whose mean age was 65.6 years.
Over 52 weeks, disease rating scores worsened by 2.45 points with nicotinamide riboside and improved by 0.27 points with placebo. Non-motor symptom burden also worsened more with nicotinamide riboside than with placebo. Four other key secondary outcomes showed no significant differences between the groups. Serious adverse events occurred in 8.3% of treated participants and 14.1% of those given placebo.
Why it matters
Parkinson disease is an illness that becomes more common with age. These findings bear on whether oral nicotinamide riboside, a nicotinamide adenine dinucleotide precursor, can act as a disease-modifying treatment in early stages of the disorder.
Caveats
The trial was conducted at 11 centres in Norway and tested a single dose over 52 weeks in patients diagnosed within the prior two years. The findings may not apply to different doses, longer treatment periods, or more advanced disease.
The paper
Show 37 more authors
Karl Bjørnar Alstadhaug, Ingunn Anundskås, Haakon Berven, Martin Biermann, Kari Anne Bjørnarå, Yamila N Torres Cleuren, Solveig E J Dalbro, David Eidelberg, Kjartan Foldnes, Gabriela Fortes, Kristoffer Haugarvoll, Karen Herlofson, Eldbjørg Hustad, Roelfien Ida HogenEsch, Gard Aasmund Skulstad Johanson, Stein Harald Johnsen, Krisztina Kunszt, Simon Kverneng, Aliaksei Labusau, Ingeborg Haugesag Lie, Hallvard Lilleng, Katarina Lundervold, Christofer Lundqvist, Yilong Ma, Adrian McCann, Tormund Haugland Njølstad, Lasse Pihlstrøm, Frank Riemer, Anna Kaja Rognerud, Erika Sheard, Axel Meyer Simonsen, Eline Storm, Magnus Svensen, Lilah Toker, Jon-Anders Tunold, Christian Dölle, Tim Friede,Haukeland University Hospital
JAMA · 8 Oct 2026
